All In Biotech

Drug Trial Radar · NCT00627926

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C

Last checked: Nov 19, 2026Latest source record: Aug 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,095 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,095

Actual

Start

Mar 2008

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
Tibotec Pharmaceutical Limited
First posted
Mar 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).

Conditions

  • Hepatitis C

Interventions

  • Pegylated Interferon Alfa 2aBiological

    subcutaneous injection, 180 micrograms once per week

  • TelaprevirDrug

    375 mg tablets administered orally every 8 hours at a dose of 750 mg

  • RibavirinDrug

    200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg

  • PlaceboOther

    Telaprevir matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study TreatmentTime frame: 24 weeks after last planned dose of study treatment (up to Week 72)

Locations

116 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Fresno, California

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    South Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Chicago, Illinois

  • Site not named

    Carmel, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Portland, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Laurel, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Manhasset, New York

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.